interstitial pneumonia, lung cancer, metastatic lung tumor, pneumothorax
Conditions
Interventions
From the 2nd day before an operation, ulinastatin was administered as a 30 min infusion of 300000 U for 3 consecutive days. The dose of the ulinastatin reduced by 100000 unit every 3rd day.
Sponsors
Tokyo Women's Medical University of Medicine, Department of Surgery I
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Preoperative chest CT scans IP findings were checked by a radiologist. The criteria for identifying IPF on a chest high-resolution computed tomography (HRCT) were subpleural space shadow, honeycomb formation, reticular shadow, tractional bronchitis/bronchioles etc., and consolidation. 2.IP findings such as fine crackles at the bilateral lower lung were checked by a pulmonologist. 3.Performance status of 0 to 1 4.The functions of the main organs such as bone marrow, heart, liver, and kidney are kept. Within 2 weeks before registration, the criteria are follows. White blood cell count >=3000mm3-<=12000mm3 Neutrophil count >=1500mm3-<=5000mm3 Platelet count >=50000mm3 Hemoglobin >=8g/dL Serum KL-6 >=500U/mL Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT); 2 times upper limit of normal in our hospital 5.A case that an operation under the general anesthesia is possible. 6.A case that a document agreement by the person himself was provided about examination participation.
Exclusion criteria
Exclusion criteria: 1.Having the history of allergic reaction against ulinastatin. 2.Asbestosis. 3.Chronic hypersensitivity pneumonitis. 4.Sarcoidosis. 5.Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Judging whether a side effect of the ulinastatin appeared. Evaluating the kind of the side effect, frequency, grade of the ulinastatin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Judging whether acute exacerbation of the postoperative interstitial pneumonia appeared. | — |
Countries
Japan
Outcome results
None listed